Baltimore, MD, United States of America

Ivo P Nnane

USPTO Granted Patents = 1 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ivo P Nnane: Innovator in Retinoid Research

Introduction

Ivo P Nnane is a notable inventor based in Baltimore, MD (US). He has made significant contributions to the field of retinoid research, particularly in the development of C-4 substituted retinoic acid analogs. His work focuses on innovative methods for treating various cancers and dermatological diseases.

Latest Patents

Ivo P Nnane holds a patent for "C-4 substituted retinoids - C-4 substituted retinoic acid analogs, synthesis methods of C-4 substituted retinoic acid analogs and methods of using C-4 substituted retinoic acid analogs to treat various cancers and dermatological diseases and conditions." This patent includes C-4 all-trans retinoic acid (ATRA) and 13-cis retinoic acid (13-CRA) analogs. The C-4 substituted retinoic acid analogs inhibit ATRA 4-hydroxylase activity, thereby inhibiting the catabolism of ATRA. Additionally, these analogs exhibit ATRA-mimetic activity, which is crucial for their therapeutic potential.

Career Highlights

Ivo P Nnane is affiliated with the University System of Maryland, where he conducts his research. His innovative work has led to advancements in the understanding and application of retinoic acid analogs in medical treatments. His contributions are recognized within the scientific community for their potential impact on cancer therapy and dermatological conditions.

Collaborations

Ivo has collaborated with esteemed colleagues such as Vincent C O Njar and Angela M H Brodie. These partnerships have fostered a collaborative environment that enhances research outcomes and drives innovation in retinoid applications.

Conclusion

Ivo P Nnane's work in the field of retinoid research exemplifies the importance of innovation in medical science. His patented developments in C-4 substituted retinoic acid analogs hold promise for advancing treatment options for various diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…